药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Brompheniramine
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.
Brompheniramine
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.
Brompheniramine
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Budesonide.
Brompheniramine
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Budesonide.
Brompheniramine
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Budesonide.
Brompheniramine
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Budesonide.
Brompheniramine
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Budesonide.
Brompheniramine
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Budesonide.
Brompheniramine
TG4010
The therapeutic efficacy of TG4010 can be decreased when used in combination with Budesonide.
Brompheniramine
Vitespen
The therapeutic efficacy of Vitespen can be decreased when used in combination with Budesonide.
Brompheniramine
GI-5005
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Budesonide.
Brompheniramine
SRP 299
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Budesonide.
Brompheniramine
Rindopepimut
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Budesonide.
Brompheniramine
INGN 225
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Budesonide.
Brompheniramine
PEV3A
The therapeutic efficacy of PEV3A can be decreased when used in combination with Budesonide.
Brompheniramine
G17DT
The therapeutic efficacy of G17DT can be decreased when used in combination with Budesonide.
Brompheniramine
Gitoformate
The risk or severity of adverse effects can be increased when Budesonide is combined with Gitoformate.
Brompheniramine
Lanatoside C
The risk or severity of adverse effects can be increased when Budesonide is combined with Lanatoside C.
Brompheniramine
Deslanoside
The risk or severity of adverse effects can be increased when Budesonide is combined with Deslanoside.
Brompheniramine
Acetyldigoxin
The risk or severity of adverse effects can be increased when Budesonide is combined with Acetyldigoxin.